Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 11/20 | 0.81 |
| ▸ | SSTR2 | P30874 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | CARM1 | Q86X55 | 4/20 | 0.35 |
| ▸ | IGF1R | P08069 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
| ▸ | JAK3 | P52333 | 1/20 | 0.34 |
| ▸ | USP1 | O94782 | 1/20 | 0.33 |
| ▸ | WDR48 | Q8TAF3 | 1/20 | 0.33 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.33 |
| ▸ | GAS6 | Q14393 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Toreforant SCHEMBL1535698 | 0.90 | HRH4 (1.00) | HRH4SSTR2KCNH2CARM1IGF1R | |
| Toreforant SCHEMBL29378793 | 0.90 | HRH4 (1.00) | HRH4SSTR2KCNH2CARM1IGF1R | |
| SCHEMBL2909393 | 0.87 | HRH4 (0.85) | HRH4JAK2JAK1JAK3USP1 | |
| SCHEMBL2906625 | 0.87 | HRH4 (0.82) | HRH4SSTR2KCNH2CARM1IGF1R | |
| SCHEMBL2912375 | 0.87 | HRH4 (0.82) | HRH4SSTR2KCNH2CARM1IGF1R | |
| SCHEMBL2906644 | 0.86 | HRH4 (0.80) | HRH4SSTR2KCNH2CARM1IGF1R | |
| Toreforant SCHEMBL16010698 | 0.85 | HRH4 (0.90) | HRH4SSTR2KCNH2IGF1RCYP3A4 | |
| SCHEMBL2910187 | 0.84 | HRH4 (1.00) | HRH4 | |
| Toreforant SCHEMBL16010696 | 0.84 | HRH4 (0.85) | HRH4SSTR2KCNH2IGF1RCYP3A4 | |
| Toreforant SCHEMBL16010707 | 0.84 | HRH4 (0.84) | HRH4SSTR2KCNH2IGF1RCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9365548-B2 | Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2016-06-14 | — | — | US | claimed |
| US-20150148361-A1 | Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2015-05-28 | — | — | US | claimed |
| US-8343989-B2 | Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2013-01-01 | — | — | US | claimed |
| US-20100256373-A1 | BENZOIMIDAZOL-2-YL PYRIMIDINES AND PYRAZINES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR | EDWARDS JAMES P | 2010-10-07 | — | — | US | claimed |
| EP-2007752-B1 | BENZOIMIDAZOL-2-YL PYRIMIDINES AND PYRAZINES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2010-08-18 | — | — | EP | claimed |
| US-20090137608-A1 | Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor | EDWARDS JAMES P | 2009-05-28 | — | — | US | claimed |
| EP-2007752-A4 | BENZOIMIDAZOL-2-YL PYRIMIDINES AND PYRAZINES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2009-04-22 | — | — | EP | claimed |
| US-7507737-B2 | Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4receptor | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-03-24 | — | — | US | claimed |
| EP-2007752-A2 | BENZOIMIDAZOL-2-YL PYRIMIDINES AND PYRAZINES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-12-31 | — | — | EP | claimed |
| WO-2007117399-A2 | BENZOIMIDAZOL-2-YL PYRIMIDINES AND PYRAZINES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-18 | — | — | WO | claimed |
| US-20070244126-A1 | Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-10-18 | — | — | US | claimed |
| US-9365548-B2 | Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2016-06-14 | — | — | US | disclosed |
| US-9365548-B2 | Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2016-06-14 | — | — | US | disclosed |
| US-20150148361-A1 | Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2015-05-28 | — | — | US | disclosed |
| US-20150148361-A1 | Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA NV (BE) | 2015-05-28 | — | — | US | disclosed |
| WO-2007117399-A2 | BENZOIMIDAZOL-2-YL PYRIMIDINES AND PYRAZINES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-18 | — | — | WO | disclosed |
| WO-2007117399-A2 | BENZOIMIDAZOL-2-YL PYRIMIDINES AND PYRAZINES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-10-18 | — | — | WO | disclosed |
| US-20070244126-A1 | Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-10-18 | — | — | US | disclosed |
| US-20070244126-A1 | Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-10-18 | — | — | US | disclosed |
| US-20070244126-A1 | Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor | JANSSEN PHARMACEUTICA, N.V. (BE) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244126-A1 | Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor | HRH4, HRH2, HRH3 | HRH4 1/4885SSTR2 577/4885KCNH2 507/4885 |
| US-20090137608-A1 | Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor | HRH4, HRH2, HRH3 | HRH4 1/4885SSTR2 727/4885KCNH2 608/4885 |
| US-20100256373-A1 | BENZOIMIDAZOL-2-YL PYRIMIDINES AND PYRAZINES AS MODULATORS OF THE HISTAMINE H4 RECEPTOR | HRH4, HRH2, HRH3 | HRH4 1/4885SSTR2 727/4885KCNH2 608/4885 |
| US-20150148361-A1 | Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor | HRH4, HRH2, HRH3 | HRH4 1/4885SSTR2 577/4885KCNH2 507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.